Approval · Notice of Compliance 10523 · 2009
CEFPROZIL TABLETS: Notice of Compliance 10523
Issued August 20, 2009
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 10523
- Date
- August 20, 2009
- Company
- Ranbaxy Pharmaceuticals Canada Inc.Brampton, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Additional product name
- Therapeutic class
- Antibiotic
- Canadian reference product
- CEFZIL (Bristol-Myers Squibb Canada)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| CEFPROZIL TABLETS | 02332035 | Cancelled Pre Market |
| CEFPROZIL TABLETS | 02332043 | Cancelled Pre Market |
Medicinal ingredients
- CEFPROZIL MONOHYDRATE 250 MG per TAB
- CEFPROZIL MONOHYDRATE 500 MG per TAB